Search In this Thesis
   Search In this Thesis  
العنوان
Occult Hepatitis (B) Virus Infection among Patients who Have Received Direct Acting Antiviral Drugs For Hepatitis (C) Virus infection /
المؤلف
Elghamry, Osama Ebrahim Ali.
هيئة الاعداد
باحث / سامة إبراهيم علي أحمد الغمرى
مشرف / سامى عيسى عبدالوهاب
مشرف / محمد محمد رفاعى خليل
الموضوع
Zagazig University Faculty of Medicine<br>Department of Tropical Medicine
تاريخ النشر
2021.
عدد الصفحات
131 p. :
اللغة
الإنجليزية
الدرجة
ماجستير
التخصص
الصحة العامة والصحة البيئية والمهنية
الناشر
تاريخ الإجازة
1/1/2021
مكان الإجازة
جامعة الزقازيق - كلية الطب البشرى - المناطق الحارة
الفهرس
Only 14 pages are availabe for public view

from 157

from 157

Abstract

Occult HBV infection (OBI) is defined as the detection of HBV DNA (in blood and/or liver tissue) without detectable HBsAg with or without anti-HBc or anti-HBs. OBI can be classified into 2 groups, seropositive OBI; anti-HBc and/or anti-hepatitis B surface (antiHBs) positive, Seropositive-OBI develops when serum test results for HBsAg become negative after acute hepatitis or when HBsAg is cleared during the course ofchronichepatitisB.seronegative OBI (anti-HBc and antiHBs negative), on the basis of the HBV antibody profile. The clinical importance of occult HBV infection may be noticed in the following clinical contexts: transmission of HBV infection after blood transfusion and organ transplantation, reactivation of chronic hepatitis B withexposuretoimmunosuppression and implication in chronic liver diseases (CLD) especially with cryptogenic chronic liver diseases, HCV-related chronic liver diseases and hepatocellular carcinoma. The present study was designed to determine the prevalence of occult HBV infection in HCV related chronic liver disease and to investigate the possible role of occult HBV infection in HCV related chronic liver disease by clarifying the clinical and laboratory features of occult HBV infection in HCV related chronic liver disease, taking into consideration that Egypt represents an area of high HCV prevalence. 2021 [SUMMARY].